(aR,3aS,4S,6S,7aR)-六氢-3a,8,8-三甲基-alpha-(2-甲基丙基)-4,6-甲桥-1,3,2-苯并二氧硼烷-2-甲胺 2,2,2-三氟乙酸盐 (179324-87-9)

(ALPHAR,3AS,4S,6S,7AR)-六氢-3A,8,8-三甲基-ALPHA-(2-甲基丙基)-4,6-甲撑-1,3,2-苯并二氧杂BOROLE-2-甲胺2,2,2-三氟乙酸酯;

(R)-1-氨基-3-甲基丁基硼酸蒎烷二醇酯三氟醋酸盐;

(1R)-(s)-蒎二醇1-三氟乙酸铵-3-甲基丁烷-1-硼;

AR,3AS,4S,6S,7AR)-六氢-3A,8,8-三甲基-ALPHA-(2-甲基丙基)-4,6-甲桥-1,3,2-苯并二氧硼烷-2-甲胺2,2,2-三氟乙酸盐,保特佐米(硼替佐米)中间体;

硼替佐米中间体1;

(R)-六氢-三甲基-(2-甲基丙基)-甲桥-苯并二氧硼烷-甲胺-三氟乙酸盐;

(1R)-3-Methyl-1-[(1S,2S,6R,8S)-2,9,9-trimethyl-3,5-dioxa-4-boratricyclo[6.1.1.0]dec-4-yl]-1-butanamine trifluoroacetate (1:1);

(1R)-3-Methyl-1-[(1S,2S,6R,8S)-2,9,9-trimethyl-3,5-dioxa-4-boratricyclo[6.1.1.0]dec-4-yl]butan-1-amine trifluoroacetate (1:1);

(aR,3aS,4S,6S,7aR)-Hexahydro-3a,8,8-trimethyl-α-(2-methylpropyl)-4,6-methano-1,3,2-benzodioxaborole-2-methanamine 2,2,2-trifluoroacetate;

(R)-BoroLeu-(+)-Pinanediol trifluoroacetate;

(1R)-3-methyl-1-[(3aS,4S,6S,7aR)-3a,5,5-trimethylhexahydro-4,6-methano-1,3,2-benzodioxaborol-2-yl]butan-1-amine trifluoroacetate (1:1);

Acetic acid, 2,2,2-trifluoro-, compd. with (αR,3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-α-(2-methylpropyl)-4,6-methano-1,3,2-benzodioxaborole-2-methanamine (1:1);

Bortezomib Intermediate 1;

(aR,3aS,4S,6S,7aR)-Hexahydro-3a,8,8-trimethyl-alpha-(2-methylpropyl)-4,6-methano-1,3,2-benzodioxaborole-2-methanamine 2,2,2-trifluoroacetate;